The tissue kallikrein level in the nasal wash was measured before and after 4-week administration of oxatomide (30 mg per day) in 9 patients with perennial allergy. It was found that tissue kallikrein level in the nasal wash obtained following provocation tests significantly decreased from 6.05 ± 4.43 (10-10 mol/hour/L)to 1.84 ± 0.93 (10-10 mol/hour/L) after the administration of oxatomide. Improvement in subjective symptoms was also observed in all patients after the administration. These results would indicate that kinin in the system is actively involved in the pathogenesis of nasal allergy.
Get full access to this article
View all access options for this article.
References
1.
PierceJ.V., and WebsterM.Human plasma kallidins: isolation and chemical studies. Biochem. Biophys. Res.Commun5: 353–357, 1961.
2.
ErdosE.G.Bradykinin, kallidin and kallikrein: Handbook of Experimental Pharmacology, XXV suppl., Berlin: Springer-Verlag,428, 1979.
3.
Oh-ishiS.Activation of kinins. In Kinins and Angiotensin.MatuoH., and KatoriM. (Eds), Tokyo: Koudan Publishers, 17–18, 1994.
4.
Oh-ishiS.Biological operation of kallikrein and kinins. In Kallikrein and Kinins.MoriyaH. (Ed), Tokyo: Koudan Publishers, 71–77, 1982.
5.
JohnsonA.R., and ErdosE.G.Release of histamine from mast cells by vasoactive peptides.Proc Soc Exp Biol Med142: 1252–1256, 1972.
6.
DevillierP., RenouxM., GiroudJ.P.Peptides and histamine release from rat peritoneal mast cells.Eur J Pharmacol117: 89–96, 1985.
7.
KatoriS.Medicinal action of kinins. In Around the Kinins.SuzukiY., and KatoriS. (Eds), Tokyo: Chugai Medical Publishers, 120–147, 1977.
8.
ProudD., TogiasA., NaclerioR.M.Kinins are generated in vivo following nasal airway challenge of allergic individuals with allergen.J Clin Invest72: 1678–1685, 1983.
9.
NishiyamaK.Kinins and kallikrein in nasal secretion after antigen challenge in patient with allergic rhinitis.J Otolaryngol Jpn97: 1512–1522, 1994.
10.
AsanoM., InamuraN., HatoriC.The identification of an orally active, nonpeptide bradykinin B2 receptor antagonist, FR173657.Br J Pharmacol120: 617–624, 1997.
11.
OkudaM., KatauraA., EnomotoK.Clinical evaluation of antiallergic KW-4354 (Oxatomide), on allergic rhinitis.Ziten27: 386–405, 1984.
12.
TasakaK., AkagiM., MioM.Inhibitory effects of oxatomide on intracellular Ca mobilization, Ca uptake and histamine release, using rat peritoneal mast cells.Int Arch Allergy Appl Immunol83: 348–353, 1987.
13.
MnabeH., OhmoriK., TomiokaH.Oxatomide inhibits the release of chemical mediators from human lung tissues and from granulocytes.Int Arch Allergy Immunol87: 91–97, 1988.
14.
KosakaY., KawabeH., and IshiiA.Oxatomide inhibits the release of bronchoconstrictor arachidonic acid metabolites (iLTC4 and PGD2) from rat mast cells and guinea-pig lung.Agents and Actions21: 32–37, 1987.
JinH.Y., KatoriM., MajimaM.Increased secretion of glandular kallikrein in the bronchial washings induced by intravenous injection of leukotriene C4 in guinea pigs.Br Pharmacol105: 632–638, 1992.
18.
MoritaT., KataH., IwanagaS.New fluorogenic substrates for alphathrombin, factor Xa, Kallikrein, and urokinase.J Biochem82: 1495–1498, 1977.
19.
Oh-ishiS., and KatoriM.Fluorimetric assay for plasma prekallikrein using peptidymethyl-coumarinyl-amide as a substrate.Thromb Res551–559, 1979.
